With continued exploration of natural endogenous ERRα ligands and understanding of the regulation of HIF-1α, the key goal in the future is to develop drugs that regulate the transcriptional activity of HIF-1α/ERRα to prevent and treat metabolism-related malignant tumors and other diseases. This evidence concerns the gene ESRRA and cancer.